Tuesday January 21, 2020

Price still isn’t right for Biogen’s blockbuster drug

HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion

Susan Mitchell

Deputy Editor and Health Editor

3rd March, 2019
Michel Vounatsos, CEO, Biogen n Vounatsos was paid $13.6 million in pay, shares and other compensation in 2017

Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.

It is being reimbursed by numerous health systems across Europe - but to varying degrees.

The HSE told Biogen that it would not reimburse Spinraza at the price it was offering.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Breast screening is fallible, and with potential extra costs due to legal actions, questions about the viability of the programme are invevitable

John Crown | 2 days ago

Inquest report calls for 24-hour consultant cover after delay in treatment led to death of Wexford patient

Susan Mitchell | 1 week ago

HSE plans to implement HPV screening test ‘during Q1 this year’

Susan Mitchell | 1 week ago